The Role of mRNA Modifications in Bone Diseases

Zehui Li, Keyu Meng, Shanwei Lan, Zhengda Ren, Zhongming Lai, Xiang Ao, Zhongyuan Liu, Jiajia Xu, Xiaoyi Mo, Zhongmin ZhangInternational Journal of Biological Sciences 2025 · DOI

Abstract

As a type of epigenetic modifications, mRNA modifications regulate the metabolism of mRNAs, thereby influencing gene expression. Previous studies have indicated that dysregulation of mRNA modifications is closely associated with the occurrence and progression of bone diseases (BDs). In this study, we first introduced the dynamic regulatory processes of five major mRNA modifications and their effects on the nucleus export, stability, and translation of mRNAs. We then summarized the mechanisms of mRNA modifications involved in the development of osteoporosis, osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, fractures, osteomyelitis, and osteosarcoma. Finally, we reviewed therapeutic strategies for BDs based on the above mechanisms, focusing on regulating osteoblast and osteoclast differentiation, inhibiting cellular senescence and injury, and alleviating inflammation. This review identified mRNA modifications as potential targets for treating BDs and proposes perspectives on the diversity, targetability, and safety of mRNA-modifying therapies.

Introduction

Bone diseases (BDs), such as osteoporosis and osteoarthritis, are leading causes of disability worldwide. While traditional genetics and DNA-level epigenetics have been studied for decades, a newer frontier has emerged: the epitranscriptome. This layer of chemical modifications on mRNA acts as a dynamic switch that controls mRNA stability, export, and translation, dictating the fate of bone cells and offering promising new targets for therapy.

Regulatory Machinery of the Epitranscriptome

The epitranscriptome consists of over 170 types of chemical tags added to RNA. This review focuses on five major modifications: m6A, m1A, m7G, ac4C, and m5C. The regulatory machinery for these modifications is categorized into three functional groups:

  • Writers: Enzymes that "install" the chemical tags (e.g., METTL3, METTL14, NAT10).
  • Erasers: Enzymes that remove the tags, making the process reversible (e.g., FTO, ALKBH5).
  • Readers: Proteins that recognize and bind to these tags to trigger biological actions like mRNA degradation or protein synthesis (e.g., YTHDF family, IGF2BPs).
Dynamic regulatory processes of five major mRNA modifications and their effects on mRNA metabolism.

The biological outcome of these modifications often depends on their position within the mRNA transcript. For example, m1A modifications in the 5’ UTR typically block translation, while those in the coding sequence (CDS) can enhance it. Furthermore, the same regulator can have opposite effects depending on the cell type; for instance, METTL14 deficiency in osteoporosis promotes bone loss by inhibiting osteoblast differentiation while simultaneously accelerating osteoclast activity.

Pathological Mechanisms in Bone Diseases

Dysregulation of these "writers," "erasers," and "readers" is a hallmark of various bone pathologies, as summarized below:

Osteoporosis and Osteoarthritis

In osteoporosis, the downregulation of the writer METTL14 leads to the decay of essential mRNAs like SIRT1 and Beclin-1, disrupting bone homeostasis. In osteoarthritis, the upregulation of METTL3 increases the expression of pro-inflammatory genes and triggers "pyroptosis" (programmed inflammatory cell death) in cartilage cells.

Rheumatoid Arthritis and Osteosarcoma

In rheumatoid arthritis, modifications regulate the activation of fibroblast-like synoviocytes (FLSs) and the production of inflammatory cytokines. In osteosarcoma (bone cancer), modifications like ac4C and m5C are hijacked by tumor cells to stabilize mRNAs involved in glycolysis and fatty acid metabolism, providing the metabolic "fuel" needed for rapid growth and drug resistance.

Mechanisms of mRNA modifications in various bone diseases including osteoporosis, osteoarthritis, and osteosarcoma.

Therapeutic Potential and Future Perspectives

The identification of these pathways opens new avenues for therapy. Experimental strategies include using viral vectors (like AAV or Lentivirus) to restore deficient "writer" levels or using small-molecule inhibitors (like STM2457) to block overactive "erasers" or "writers" to reverse bone loss or inhibit tumor growth.

However, several hurdles remain before these findings can reach the clinic:

  • Off-Target Effects: Because a single regulator can affect thousands of different mRNAs, global modulation risks significant side effects. Developing bone-targeted delivery systems (e.g., nanoparticle-based) is essential.
  • Knowledge Gaps: The specific "erasers" or "readers" for certain modifications like m7G and ac4C remain unidentified.
  • Complexity: mRNA modifications interact with non-coding RNAs and DNA methylation in complex networks that are not yet fully mapped.
  • Safety: The long-term safety of modifying the epitranscriptome in humans remains unknown, requiring rigorous clinical validation.

Summary updated

Abstract

As a type of epigenetic modifications, mRNA modifications regulate the metabolism of mRNAs, thereby influencing gene expression. Previous studies have indicated that dysregulation of mRNA modifications is closely associated with the occurrence and progression of bone diseases (BDs). In this study, we first introduced the dynamic regulatory processes of five major mRNA modifications and their effects on the nucleus export, stability, and translation of mRNAs. We then summarized the mechanisms of mRNA modifications involved in the development of osteoporosis, osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, fractures, osteomyelitis, and osteosarcoma. Finally, we reviewed therapeutic strategies for BDs based on the above mechanisms, focusing on regulating osteoblast and osteoclast differentiation, inhibiting cellular senescence and injury, and alleviating inflammation. This review identified mRNA modifications as potential targets for treating BDs and proposes perspectives on the diversity, targetability, and safety of mRNA-modifying therapies.
BibTeX
@article{li2025role,
  author = {Zehui Li and Keyu Meng and Shanwei Lan and Zhengda Ren and Zhongming Lai and Xiang Ao and Zhongyuan Liu and Jiajia Xu and Xiaoyi Mo and Zhongmin Zhang},
  title = {{The Role of mRNA Modifications in Bone Diseases}},
  journal = {International Journal of Biological Sciences},
  year = {2025},
  doi = {10.7150/ijbs.104460},
}
Figure